Rocket Pharmaceuticals Gets Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401

  • Jonathan Schwartz,

Press/Media

Period28 Nov 2020

Media coverage

1

Media coverage

  • TitleRocket Pharmaceuticals Gets Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401
    Media name/outletProfessional Services Close-Up
    Country/TerritoryUnited States
    Date28/11/20
    PersonsJonathan Schwartz,
View all 1
View less